Bispecifics
Bispecifics
Strategies for Stable, High-Concentration Bispecific Antibody Formulations
Strategies for Stable, High-Concentration Bispecific Antibody Formulations
Turn formulation from a bottleneck into a driver of clinical or commercial success. Explore the science in our white paper or join us live for expert insights on October 28.
Turn formulation from a bottleneck into a driver of clinical or commercial success. Explore the science in our white paper or join us live for expert insights on October 28.
Bispecific antibodies hold enormous therapeutic potential—but their formulation can be uniquely challenging. From stability issues to high-concentration products, many promising molecules fail to progress.
Bispecific antibodies hold enormous therapeutic potential—but their formulation can be uniquely challenging. From stability issues to high-concentration products, many promising molecules fail to progress.
At Leukocare, we’ve combined advanced data science and systematic excipient selection to overcome these pitfalls. On this page, you’ll find two ways to explore our approach:
A comprehensive white paper for in-depth insights
A webinar to discuss strategies with our experts
At Leukocare, we’ve combined advanced data science and systematic excipient selection to overcome these pitfalls. On this page, you’ll find two ways to explore our approach:
A comprehensive white paper for in-depth insights
A webinar to discuss strategies with our experts
Overcoming the Formulation Roadblocks of Bispecific Antibodies
This white paper explores the unique challenges of bsAb formulation and how data-driven
molecular modeling can shorten timelines, reduce failures, and optimize stability.
Our latest white paper explores:
· The critical pitfalls in bispecific formulation
· How data-driven strategies streamline excipient selection
· A real-world case study: stable, high-concentration bispecific for Phase 2 trials
Our latest white paper explores:
· The critical pitfalls in bispecific
formulation
· How data-driven strategies
streamline excipient selection
· A real-world case study: stable,
high-concentration bispecific for
Phase 2 trials
Here's what our customers have to say:
Jie Die
Head DP, Incyte
"Leukocare has worked closely with our team, adapting to our processes and timelines. Their flexible and collaborative approach has supported our formulation development well. Their tailored DoE approach has been aligned with our needs and has consistently led to conclusive, science-based results. Their way of working has complemented our internal efforts effectively."
Jie Die
Head DP, Incyte
"Leukocare has worked closely with our team, adapting to our processes and timelines. Their flexible and collaborative approach has supported our formulation development well. Their tailored DoE approach has been aligned with our needs and has consistently led to conclusive, science-based results. Their way of working has complemented our internal efforts effectively."
Jie Die
Head DP, Incyte
"Leukocare has worked closely with our team, adapting to our processes and timelines. Their flexible and collaborative approach has supported our formulation development well. Their tailored DoE approach has been aligned with our needs and has consistently led to conclusive, science-based results. Their way of working has complemented our internal efforts effectively."
Contact
Ready to talk about your bispecific formulation strategy?
Our experts work with leading biotech companies to solve complex formulation challenges. If you’d like to discuss your molecule and explore tailored solutions, we’d be happy to connect.
Reach out now
Ulrike Konrad - VP Business Development
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Ready to talk about your bispecific formulation strategy?